Diagnostic Rentability of Screening for Associated Conditions in Calcium Pyrophosphate Deposition Disease Patients

Chondrocalcinosis Clinical Trial

Official title:

Appraisal of the Diagnostic Rentability of Thorough Analytical Screening Searching Associated Conditions in Patients Newly Diagnosed With Calcium Pyrophosphate Dihydrate Deposition Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00453128
• Other study ID #: SGR1
• Status: Completed
• Phase: N/A
• First received: March 26, 2007
• Last updated: March 27, 2007
• Start date: January 1997
• Est. completion date: December 2006

Study information

• Verified date: March 2007
• Source: Sociedade Galega de Reumatoloxía
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine whether thorough analytical evaluation is useful to diagnose metabolic conditions associated to calcium pyrophosphate deposition disease.

Description:

The diagnostic usefulness of screening for hyperparathyroidism, hemochromatosis, hypothyroidism and hypophosphatasia in patients diagnosed with calcium pyrophosphate dihydrate (CPPD) deposition disease is uncertain.

Patients diagnosed with CPPD deposition disease were compared to patients with rheumatoid arthritis and psoriatic arthritis over a 9-year period. All patients were prospectively followed for at least 12 months. Serum calcium, phosphorus, alkaline phosphatase, thyroid-stimulating hormone, ferritin, iron, and total iron binding capacity were determined in all patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 240
• Est. completion date: December 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients diagnosed as having calcium pyrophosphate dihydrate deposition disease.

Exclusion Criteria:

• Patients mimicking a rheumatoid arthritis disease, with positive rheumatoid factor or with psoriasis.

Study Design

Observational Model: Case Control, Time Perspective: Longitudinal

Related Conditions & MeSH terms

• Chondrocalcinosis

Locations

Country	Name	City	State
Spain	Meixoeiro Hospital	Vigo	Pontevedra

Sponsors (1)

Lead Sponsor	Collaborator
Sociedade Galega de Reumatoloxía

Country where clinical trial is conducted

Spain,